Avaleht › Äge müeloidne leukeemia › Florida › Miami
Äge müeloidne leukeemia kliinilised uuringud linnas Miami, FL
24 uuringut haiguse Äge müeloidne leukeemia jaoks otsivad osalejaid linnas Miami ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
VärbamineFaas 2
- Miami Cancer Institute, Miami
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
VärbamineFaas 2
- Miami Cancer Institute, Miami
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
VärbamineFaas 2
- Miami Cancer Institute, Miami
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
VärbamineFaas 2
- Miami Cancer Institute, Miami
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
VärbamineFaas 2
- Miami Cancer Institute, Miami
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
VärbamineFaas 3
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
VärbamineFaas 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
VärbamineFaas 1
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
VärbamineFaas 1/2
- Nicklaus Children's Hospital, Miami
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
VärbamineFaas 3
- University of Miami, Miami
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
Värbamine
- University of Miami, Miami
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
VärbamineFaas 2/3
- Bioresearch Partners, Miami
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
VärbamineFaas 2
- University of Miami, Miami
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
VärbamineVaatlusuuring
- University of Miami (peds), Miami
- Niklaus Children's Hospital, Miami
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
VärbamineFaas 2/3
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
VärbamineFaas 2
- University of Miami, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
VärbamineFaas 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
VärbamineFaas 2
- University of Miami, Miami
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
VärbamineFaas 1
- University of Miami Health System, Miami
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
VärbamineFaas 1
- University of Miami, Miami
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
VärbamineFaas 1
- Sylvester Comprehensive Cancer Center, Miami
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
VärbamineFaas 1/2
- University of Miami - Miller School of Medicine, Miami
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
VärbamineTerved vabatahtlikud oodatud
- University of Miami, Miami
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
VärbamineFaas 1
- University of Miami, Miami
Äge müeloidne leukeemia uuringud teistes linnades
- Houston, TX85 uuringut
- New York City, NY51 uuringut
- Boston, MA44 uuringut
- Baldwin Park, CA40 uuringut
- Seattle, WA40 uuringut
- Columbus, OH35 uuringut
- Philadelphia, PA34 uuringut
- Durham, NC33 uuringut
- Atlanta, GA30 uuringut
- Tampa, FL29 uuringut
- Chicago, IL26 uuringut
- Portland, OR25 uuringut
Muud uuringud linnas Miami
- Rinnavähk42 uuringut
- Vähk (kõik liigid)36 uuringut
- Mitteväikerakuline kopsuvähk31 uuringut
- Eesnäärmevähk27 uuringut
- Rasvumine27 uuringut
- Metastaatiline vähk24 uuringut
- Munasarjavähk23 uuringut
- Ülekaalulisus23 uuringut
- Müeloom21 uuringut
- Haavandiline koliit21 uuringut
- Alzheimeri tõbi20 uuringut
- Kopsuvähk20 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.